Review of resistance of ocular isolates of Pseudomonas aeruginosa and staphylococci from keratitis to ciprofloxacin, gentamicin and cephalosporins

Clinical and Experimental Optometry

Volumn 94, Issue 2, 2011, Pages 161-168

  Willcox, Mark D P ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cephalosporin; Ciprofloxacin; Gentamicin; Pseudomonas; Staphylococcus

Indexed keywords

ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; GENTAMICIN;

ANTIBIOTIC RESISTANCE; DRUG COMBINATION; DRUG EFFECT; HUMAN; KERATITIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CEPHALOSPORINS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; GENTAMICINS; HUMANS; KERATITIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 79951972127     PISSN: 08164622     EISSN: 14440938     Source Type: Journal    
DOI: 10.1111/j.1444-0938.2010.00536.x     Document Type: Review

References (55)

1. Pepose JS, Wilhelmus KR. Divergent approaches to the management of corneal ulcers. Am J Ophthalmol 1992; 114: 630-632.
2. Keay L, Edwards K, Stapleton F. Referral pathways and management of contact lens-related microbial keratitis in Australia and New Zealand. Clin Experiment Ophthalmol 2008; 36: 209-216.
3. Jones DB. Initial therapy of suspected microbial corneal ulcers. II. Specific antibiotic therapy based on corneal smears. Surv Ophthalmol 1979; 24: 97, 105-116.
4. O'Brien TP. Management of bacterial keratitis: beyond exorcism towards consideration of organism and host factors. Eye 2003; 17: 957-974.
5. McAllum PJ, McGhee CN. Prescribing trends in infectious keratitis: a survey of New Zealand ophthalmologists. Clin Experiment Ophthalmol 2003; 31: 496-504.
6. Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. Am J Ophthalmol 1991; 112: 34S-47S.
7. Honig MA, Cohen EJ, Rapuano CJ, Laibson PR. Corneal ulcers and the use of topical fluoroquinolones. CLAO J 1999; 25: 200-203.
8. O'Brien TP, Maguire MG, Fink NE, Alfonso E, McDonnell P. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol 1995; 113: 1257-1265.
9. Hyndiuk RA, Eiferman RA, Caldwell DR, Rosenwasser GO, Santos CI, Katz HR, Badrinath SS etal. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Ophthalmology 1996; 103: 1854-1862.
10. Parks DJ, Abrams DA, Sarfarazi FA, Katz HR. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis. Am J Ophthalmol 1993; 115: 471-477.
11. The Ofloxacin Study Group. Ofloxacin monotherapy for the primary treatment of microbial keratitis: a double-masked, randomized, controlled trial with conventional dual therapy. Ophthalmology 1997; 104: 1902-1909.
12. Ly CN, Pham JN, Badenoch PR, Bell SM, Hawkins G, Rafferty DL, McClellan KA. Bacteria commonly isolated from keratitis specimens retain antibiotic susceptibility to fluoroquinolones and gentamicin plus cephalothin. Clin Experiment Ophthalmol 2006; 34: 44-50.
13. Schein OD, Glynn RJ, Poggio EC, Seddon JM, Kenyon KR, the Microbial Keratitis Study Group. The relative risk of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. A case-control study. N Engl J Med 1989; 321: 773-8.
14. Green M, Apel A, Stapleton F. Risk factors and causative organisms in microbial keratitis. Cornea 2008; 27: 22-27.
15. McDonnell PJ, Nobe J, Gauderman WJ, Lee P, Aiello A, Trousdale M. Community care of corneal ulcers. Am J Ophthalmol 1992; 114: 531-538.
16. Keay L, Edwards K, Dart J, Stapleton F. Grading contact lens-related microbial keratitis: relevance to disease burden. Optom Vis Sci 2008; 85: 531-537.
17. Keay L, Edwards K, Naduvilath T, Taylor HR, Snibson GR, Forde K, Stapleton F. Microbial keratitis predisposing factors and morbidity. Ophthalmology 2006; 113: 109-116.
18. Wilhelmus KR, Abshire RL, Schlech BA. Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis. Arch Ophthalmol 2003; 121: 1229-1233.
19. Rodman RC, Spisak S, Sugar A, Meyer RF, Soong HK, Musch DC. The utility of culturing corneal ulcers in a tertiary referral center versus a general ophthalmology clinic. Ophthalmology 1997; 104: 1897-1901.
20. Hall RC, McKellar MJ. Bacterial keratitis in Christchurch, New Zealand, 1997-2001. Clin Experiment Ophthalmol 2004; 32: 478-481.
21. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology 2000; 107: 1497-1502.
22. Yeh DL, Stinnett SS, Afshari NA. Analysis of bacterial cultures in infectious keratitis, 1997 to 2004. Am J Ophthalmol 2006; 142: 1066-1068.
23. Morrissey I, Burnett R, Viljoen L, Robbins M. Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001/2002. J Infect 2004; 49: 109-114.
24. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology 1999; 106: 1313-1318.
25. Marangon FB, Miller D, Muallem MS, Romano AC, Alfonso EC. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. Am J Ophthalmol 2004; 137: 453-458.
26. Freidlin J, Acharya N, Lietman TM, Cevallos V, Whitcher JP, Margolis TP. Spectrum of eye disease caused by methicillin-resistant Staphylococcus aureus. Am J Ophthalmol 2007; 144: 313-315.
27. Afshari NA, Ma JJK, Duncan SM, Pineda R, Starr CE, Decroos FC, Johnson CS etal. Trends in resistance to ciprofloxacin, cefazolin, and gentamicin in the treatment of bacterial keratitis. J Ocular Pharmacol Ther 2008; 24: 217-223.
28. Knauf HP, Silvany R, Southern RM, Risser RC, Wilson SE. Susceptibility of corneal and conjunctival pathogens to ciprofloxacin. Cornea 1996; 15: 66-71.
29. Chaudhry NA, Flynn HW Jr, Murray TG, Tabandeh H, Mello MO Jr, Miller D. Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol 1999; 128: 509-510.
30. Schaefer F, Bruttin O, Zografos L, Guex-Crosier Y. Bacterial keratitis: a prospective clinical and microbiological study. Br J Ophthalmol 2001; 85: 842-847.
31. Kunimoto DY, Sharma S, Garg P, Rao GN. In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin. Emerging resistance. Ophthalmology 1999; 106: 80-85.
32. Jayahar MB, Ramakrishnan R, Vasu S, Meenakshi R, Palaniappan R. In vitro efficacy of antibacterials against bacterial isolates from corneal ulcers. Indian J Ophthalmol 2002; 50: 109-114.
33. Sharma V, Sharma S, Garg P, Rao GN. Clinical resistance of Staphylococcus keratitis to ciprofloxacin monotherapy. Indian J Ophthalmol. 2004; 52: 287-292.
34. Garg P, Sharma S, Rao GN. Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology 1999; 106: 1319-1323.
35. Smitha S, Lalitha P, Prajna VN, Srinivasan M. Susceptibility trends of Pseudomonas species from corneal ulcers. Indian J Med Microbiol 2004; 23: 168-171.
36. Sharma S, Kunimoto DY, Garg P, Rao GN. Trends in antibiotic resistance of corneal pathogens: Part I. An analysis of commonly used ocular antibiotics. Indian J Ophthalmol 1999; 47: 95-100.
37. Chalita MR, Höfling-Lima AL, Paranhos A, Schor P, Belfort R. Shifting trends in in vitro antibiotic susceptibilities for common ocular isolates during a period of 15years. Am J Ophthalmol 2004; 137: 43-51.
38. Oliveira ADD, d'Azevedo PA, Francisco W, Höfling-Lima AL. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil. Cornea 2007; 26: 194-198.
39. Moriyama AS, Hofling-Lima Al. Contact lens-associated microbial keratitis. Arq Bras Oftalmol 2008; 71: s32-s36.
40. Höfling-Lima AL, Belfort R Jr, Moeller CTA, Branco BC, de Sousa LB, de Freitas D. In vitro antibiotic susceptibilities of ocular bacteria isolates from the cornea and conjunctiva to moxifloxacin, gatifloxacin and other fluoroquinolones. Arq Bras Oftalmol 2004; 67: 883-886.
41. Fong C-F, Hu F-R, Tseng C-H, Jong Wang I, Chen W-L, Hou Y-C. Antibiotic susceptibility of bacterial isolates from bacterial keratitis cases in a university hospital in Taiwan. Am J Ophthalmol 2007; 144: 682-689.
42. Tuft SJ, Matheson M. In vitro antibiotic resistance in bacterial keratitis in London. Br J Ophthalmol 2000; 84: 687-691.
43. Leibovitch I, Lai TF, Senarath L, Hsuan J, Selva D. Infectious keratitis in South Australia: emerging resistance to cephazolin. Eur J Ophthalmol 2005; 15: 23-26.
44. Barton MD, Pratt R, Hart WS. Antibiotic resistance in animals. Commun Dis Intell 2007; 27: S121-S126.
45. Livesey JE, Chiew YF. Antimicrobial drug utilisation in Dunedin Hospital, New Zealand, and its association with antimicrobial resistance. Pathology 2006; 38: 245-248.
46. Unal S, Garcia-Rodriguez JA. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004. Diagn Microbiol Infect Dis 2005; 53: 265-271.
47. Nimmo GR, Bell JM, Mitchell D, Gosbell IB, Pearman JW, Turnidge JD. AGAR. Antimicrobial resistance in Staphylococcus aureus in Australian teaching hospitals, 1989-1999. Microbial Drug Resist 2003; 9: 155-160.
48. Kumhar GD, Ramachandran VG, Gupta P. Bacteriological analysis of blood culture isolates from neonates in a tertiary care hospital in India. J Health Pop Nutr 2002; 20: 343-347.
49. Loureiro MM, de Moraes BA, Mendonca VL, Quadra MR, Pinheiro GS, Asensi MD. Pseudomonas aeruginosa: study of antibiotic resistance and molecular typing in hospital infection cases in a neonatal intensive care unit from Rio de Janeiro City, Brazil. Mem Inst Oswaldo Cruz 2002; 97: 387-394.
50. Willcox M, Sankaridurg PR, Zhu H, Hume E, Cole N, Conibear T, Glasson M etal. Inflammation and infection and effects of the closed eye. In: Sweeney D, ed. Silicone Hydrogels: Continuous Wear Contact lenses, 2nd ed. Oxford, UK: Butterworth-Heinemann, 2004. p. 90-125.
51. Leeming JP. Treatment of ocular infections with topical antibacterials. Clin Pharmacokinet 1999; 37: 351-360.
52. Gaynor BD, Chidambaram JD, Cevallos V, Miao Y, Miller K, Jha HC, Bhatta RC etal. Topical ocular antibiotics induce bacterial resistance at extraocular sites. Br J Ophthalmol 2005; 89: 1097-1099.
53. Arantes TEF, Cavalcanti RF, de Fátima Alves Diniz M, Severo MS, Neto JL, de Castro CMMB. Conjunctival bacterial flora and antibiotic resistance pattern in patients undergoing cataract surgery. Arq Bras Oftalmol 2006; 69: 33-36.
54. Gill SR, Pop M, DeBoy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, Gordon JI etal. Metagenomic analysis of the human distal gut microbiome. Science 2006; 312: 1355-1359.
55. Duggirala A, Joseph J, Sharma S, Nutheti R, Garg P, Das T. Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: An in vitro comparison. Indian J Ophthalmol 2007; 55: 15-19.